Loading stock data…
Haemonetics Corporation (HAE)
$75.12-2.17 (-2.81%)
Market ClosedLast close Jun 29
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Haemonetics Corporation in the Healthcare sector is trading at $75.12 with a market capitalization of $3.0B. Wall Street consensus targets $85.20 (10 analysts), implying a +13.4% move over the next 12 months. The stock is currently 14% below its 52-week high of $87.32, remaining 16.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $346.35M↑ | $338.97M↑ | $327.31M↑ | $321.39M↓ | $330.60M |
| Gross Profit | $198.21M↓ | $202.39M↑ | $194.74M↑ | $192.24M↓ | $193.05M |
| Operating Income | $52.34M↓ | $68.11M↑ | $67.08M↑ | $53.87M↑ | $50.70M |
| Net Income | -$20.15M↓ | $44.74M↑ | $38.68M↑ | $34.03M↓ | $57.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting sof...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.22%
Volume
Today's trading volume
456,773
Recent News
3 Profitable Stocks We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
Haemonetics (HAE) has redrawn its business map by merging its Plasma and Blood Center units into a single Apheresis segment and renaming its Hospital segment as MedSurg, aligning reporting with how management now runs the company. See our latest analysis for Haemonetics. Recent trading shows momentum building, with Haemonetics’ share price posting a 35.85% 1 month share price return and a 19.14% 3 month share price return. However, the 1 year total shareholder return of 4.51% highlights a...
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next
Earlier this week, Haemonetics reported quarterly results that surpassed analyst expectations for both revenue and earnings, supported by solid demand in its plasma and hospital-focused product lines. The earnings beat, combined with BofA Securities upgrading the stock on improving vascular closure and plasma performance, has sharpened investor focus on the company’s product mix and execution quality. We’ll now examine how the earnings beat and raised guidance may influence Haemonetics’...
Haemonetics (HAE) Stock Is Up, What You Need To Know
Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the company to Buy from Neutral and raised its price target to $80 from $72.